172 related articles for article (PubMed ID: 1735732)
1. Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.
Teicher BA; Herman TS; Hopkins RE; Menon K
J Cancer Res Clin Oncol; 1992; 118(2):123-8. PubMed ID: 1735732
[TBL] [Abstract][Full Text] [Related]
2. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
[TBL] [Abstract][Full Text] [Related]
3. A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.
Teicher BA; Holden SA; Ara G; Ha CS; Herman TS; Northey D
J Cancer Res Clin Oncol; 1992; 118(7):509-14. PubMed ID: 1624542
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
[TBL] [Abstract][Full Text] [Related]
5. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
Teicher BA; Bernal SD; Holden SA; Cathcart KN
Cancer Chemother Pharmacol; 1988; 21(4):281-5. PubMed ID: 3131032
[TBL] [Abstract][Full Text] [Related]
6. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
Teicher BA; Herman TS; Tanaka J; Dezube B; Pardee A; Frei E
Cancer Chemother Pharmacol; 1991; 28(1):45-50. PubMed ID: 1904012
[TBL] [Abstract][Full Text] [Related]
7. Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity.
Teicher BA; Crawford JM; Holden SA; Cathcart KN
Cancer Res; 1987 Oct; 47(19):5036-41. PubMed ID: 3113727
[TBL] [Abstract][Full Text] [Related]
8. Modulation of alkylating agents by lonidamine in vivo.
Teicher BA; Holden SA; Herman TS; Frei E
Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
[TBL] [Abstract][Full Text] [Related]
9. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity.
Teicher BA; Holden SA; Jacobs JL
Cancer Res; 1987 Jan; 47(2):513-8. PubMed ID: 3098413
[TBL] [Abstract][Full Text] [Related]
10. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
11. Enhancement by perflusion emulsion (Oxygent) and carbogen breathing of the tumor growth delay of the FSaIIC fibrosarcoma after treatment with antitumor alkylating agents.
Holden SA; Teicher BA; Ha C; Ara G; Herman TS
Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):895-8. PubMed ID: 1391529
[TBL] [Abstract][Full Text] [Related]
12. Effect of Fluosol-DA/O2 on tumor-cell and bone-marrow cytotoxicity of nitrosoureas in mice bearing FSA-II fibrosarcoma.
Teicher BA; Holden SA; Rose CM
Int J Cancer; 1986 Aug; 38(2):285-8. PubMed ID: 3089945
[TBL] [Abstract][Full Text] [Related]
13. Combination of etanidazole with cyclophosphamide and platinum complexes.
Teicher BA; Herman TS; Shulman L; Bubley G; Coleman CN; Frei E
Cancer Chemother Pharmacol; 1991; 28(3):153-8. PubMed ID: 1830248
[TBL] [Abstract][Full Text] [Related]
14. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.
Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE; Frei E
Cancer Res; 1989 Feb; 49(3):595-8. PubMed ID: 2910481
[TBL] [Abstract][Full Text] [Related]
15. Survey of the effect of adding Fluosol-DA 20%/O2 to treatment with various chemotherapeutic agents.
Teicher BA; Holden SA
Cancer Treat Rep; 1987 Feb; 71(2):173-7. PubMed ID: 3100035
[TBL] [Abstract][Full Text] [Related]
16. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.
Teicher BA; Holden SA; al-Achi A; Herman TS
Cancer Res; 1990 Jun; 50(11):3339-44. PubMed ID: 2334928
[TBL] [Abstract][Full Text] [Related]
17. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
18. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
[TBL] [Abstract][Full Text] [Related]
19. The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.
Teicher BA; Herman TS; Holden SA; Cathcart KN
Cancer Chemother Pharmacol; 1988; 21(4):286-91. PubMed ID: 3131033
[TBL] [Abstract][Full Text] [Related]
20. Effect of various oxygenation conditions and fluosol-DA on cytotoxicity and antitumor activity of bleomycin in mice.
Teicher BA; Holden SA; Cathcart KN; Herman TS
J Natl Cancer Inst; 1988 Jun; 80(8):599-603. PubMed ID: 2453675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
